Chemical, Structural, Clinical and Biological details of Antiviral agents ID: DrugRepV_2233



Chemical Information
Antiviral agent IDDrugRepV_2233
Antiviral agent nameReserpine Drug Bank
IUPAC Namemethyl (1R,15S,17R,18R,19S,20S)-6,18-dimethoxy-17-(3,4,5-trimethoxybenzoyl)oxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate PubChem
SMILES (canonical)COC1C(CC2CN3CCC4=C(C3CC2C1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC PubChem
SMILES (isomeric)CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC PubChem
Molecular FormulaC33H40N2O9 PubChem
Molecular Weight (g/mol)608.688 PubChem
InChlInChI=1S/C33H40N2O9/c1-38-19-7-8-20-21-9-10-35-16-18-13-27(44-32(36)17-11-25(39-2)30(41-4)26(12-17)40-3)31(42-5)28(33(37)43-6)22(18)15-24(35)29(21)34-23(20)14-19/h7-8,11-12,14,18,22,24,27-28,31,34H,9-10,13,15-16H2,1-6H3/t18-,22+,24-,27-,28+,31+/m1/s1 PubChem
Common NameReserpine Drug Bank
Synonyms(-)-Reserpine | (−)-reserpine | (3beta,16beta,17alpha,18beta,20alpha)-11,17-Dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylic acid methyl ester | 3,4,5-trimethoxybenzoyl methyl reserpate | Apoplon | Reserpin | Reserpine | Serpalan
Structural Information
  
Clinical Information
CategoryCardiovascular agents
Primary Indication (Clinical trial phases)Approved, Investigational Drug Bank
Biological Information
Primary Indication (Disease Category) Non Infectious Disease
Primary Indication (Disease)Hypertension | Psychotic disorder
Primary Indication (Drug target/Mode of Action) Tyrosine-protein phosphatase non-receptor type
Secondary Indication Chikungunya virus (CHIKV) NA vAc-CHIKV 26S-Rhir-EWorld Health OrganisationCDC
Secondary Indication (Approaches)Experimental
Secondary Indication (Methods)in-vitro
Secondary Indication (Model system) [cell lines/ animal models]Sf21
Secondary Indication (Mode of viral infection)Adsorption
Secondary Indication (Viral titer)2 MOI
Secondary Indication (Mode of drug delivery) Culture
Secondary Indication (Drug concentration)100 μM
Secondary Indication (Cell based assay)Fusion index-Fluorescent Intensities
Secondary Indication (Change)No significant decrease
Secondary Indication (Type of Inhibition) Percentage inhibition [ 6.9045194 % ]
ReferenceWang YM, Lu JW, Lin CC, Chin YF, Wu TY, Lin LI, Lai ZZ, Kuo SC, Ho YJ..Antiviral activities of niclosamide and nitazoxanide against chikungunya virus entry and transmissio.Antiviral Res. 2016 Nov;135:81-90. doi: 10.1016/j.antiviral.2016.10.003. Epub 2016 Oct 11. PMID:27742486 PubMed
CommentNiclosamide and nitazoxanide were able to inhibit CHIKV entry and transmission, which might provide a basis for the development of novel human drug therapies against CHIKV and other alphavirus infections.